1. Introduction {#sec1}
===============

An open nasal cannula system for delivering warm and humidified air or oxygen at higher flow rates (nasal high flow (NHF), 2--50 L/min) has been shown to assist ventilation and outcomes in the acute setting in adults and in children. Recently, NHF has been introduced for respiratory support in ICU settings, mainly in patients with acute hypoxemic respiratory failure [@bib3], [@bib6], [@bib12], but some demonstrating an improvement in hypercapnia and clinical outcomes, too [@bib6], [@bib10], [@bib11]. The mechanisms of reducing arterial CO~2~ is proposed through a reduction in nasal dead space ventilation [@bib8], [@bib9], but there are no studies in spontaneously breathing subjects. We therefore, measured tracheal CO~2~ on and off NHF in a spontaneously breathing patient with tracheostomy.

2. Case presentation {#sec2}
====================

A 62-year-old man (smoker, 60 pack years) with severe chronic obstructive pulmonary disease (COPD GOLD IV) (FEV1: 0,8 L/min), cachexia (BMI 19,8 kg/m^2^), oxygen dependency (2L/min) and hypercapnic respiratory failure with arterial CO~2~ ranging from 65 to 75 mmHg was studied during wake. His current illness included critical illness polyneuro- and myopathie after he developed an acute exacerbation of COPD and was ventilated through a tracheostomy for 1 month. He regained muscle strength after neurological rehabilitation and was admitted to our pulmonary rehabilitation unit for considering decannulation of his tracheostomy tube. At the time of this study, his tracheostomy was capped with a tracheostomy button for several days and he was able to breathe spontaneously at rest during the day and continued non-invasive ventilation (NIV) with following settings: Spontaneous/Timed (S/T)-mode, inspiratory pressure 25 cmH~2~O, expiratory pressure 5 cm H~2~O, backup rate 15/min.

3. Methods {#sec3}
==========

The patient was instrumented with intra-tracheal catheters for CO~2~ and pressure (PTRACH) measurements via sealed ports in the tracheostomy cap ([Fig. 1](#fig1){ref-type="fig"}). Tidal volume (VT) was measured by respiratory inductive plethysmography (RIP) and arterial CO~2~ was monitored transcutaneously (tc CO~2~). Inspired CO~2~ was calculated from the tidal CO~2~ tracing and tidal volume using the modified Fowler technique as previously described [@bib4], [@bib2]. The study was performed while the patient was resting in a sitting semi-recumbent position breathing effortless with 2 L/min oxygen (baseline). Nasal high flow (NHF 30 L/min mixed with 3 L/min O~2~ to match his F~I~O2 requirements) was administered repeatedly at 15-minutes intervals. Due to the higher inspiratory flow with NHF a higher oxygen concentration (3L/min) is required to achieve the same F~I~O2.

4. Results {#sec4}
==========

The effects of NHF on ventilation and arterial blood gases compared to oxygen are shown in [Fig. 2](#fig2){ref-type="fig"}. The top panel shows a 25 minute overview of experimental setup: tracheal pressure (P~TRACH~), end tidal tracheal CO~2~ (ET CO~2~), tidal volume (VT), transcutaneous CO~2~ (Tc CO~2~), inspired CO~2~, (in CO~2~). Grey bars highlight snapshots of 40 seconds at baseline (left lower panel) and NHF (right lower panel). As can be seen, NHF increased end-expiratory pressure (PEEP) by 1 cm H~2~O, reduced inspiratory CO~2~ from 6 ± 1 to 3 ± 0,5 ml, and tcCO~2~ from 68 to 63 mmHg. The reduction in inCO~2~ occurred instantly with onset of NHF (see vertical arrow in [Fig. 2](#fig2){ref-type="fig"} upper panel) when tcCO~2~ remained unchanged. While tidal volume remained similar at 290 ± 15 ml, there was a reduction in respiratory rate from 26/min to 22/min leading to a reduction in minute ventilation from 7,2--6.5 L/min (by 700 ml). Based on the mass balance equation shown below, a reduction in minute ventilation (VE) should have increased arterial CO~2~. Rather, we show a decrease in tcCO~2~, which can only be explained by a reduction in dead space ventilation (VD) exceeding 700 ml/min. Given a respiratory rate of 22/min the NHF must have led to a reduction in dead space ventilation (VD) of more than 30 mls per breath.

5. Summary and interpretation {#sec5}
=============================

We assume that the reduction in inspired CO~2~ by 50% is likely due to a washout in CO~2~ of the upper airway for the following reasons: A) it occurred instantly with onset of NHF when tcCO~2~ remained unchanged. B) the patient reduced minute ventilation on NHF by 700 ml/min and tcCO~2~ decreased which can only be explained by a reduction in dead space ventilation (VD) exceeding 700 ml/min based on the mass balance equation. This reduction was sufficient to reduce ventilatory loads as best documented by a concomitant ∼20% reduction in respiratory rate.

We also show, that in our patient, transcutaneous (arterial) CO~2~ was lowered by 7.4% with NHF. If this reduction would remain over an extended period, e.g., sleep, this magnitude of CO~2~ reduction would be similar to that using non-invasive ventilation via nasal or full face mask [@bib5], [@bib7].

6. Clinical implications {#sec6}
========================

COPD with hypercapnia is associated with increased mortality [@bib1] and current treatment options to lower hypercapnia and ventilatory loads require extensive treatment with invasive or non-invasive ventilator support [@bib5]. Our data suggest that NHF could be used as an alternative option to lower arterial CO~2~ in a subset of patients. Moreover, the clearance of anatomical dead space by NHF may be especially beneficial for subjects who have high dead space ventilation due to tachypnea or due to rapid shallow breathing pattern as in our patient. Even a small reduction of dead space would lead to a relatively high increase in alveolar volume, since the ratio of dead space to tidal volume increases during shallow breathing.

In conclusion, NHF can treat hypercapnic respiratory failure in some patients through clearance of anatomical dead space, which improves alveolar ventilation, thus leading to reduction of arterial CO2.$$PaCO_{2} = k \cdot \frac{{\overset{\cdot}{V}}_{co_{2}}}{{\overset{\cdot}{V}}_{A}} = k \cdot \frac{{\overset{\cdot}{V}}_{co_{2}}}{{\overset{\cdot}{V}}_{E} - {\overset{\cdot}{V}}_{D}}$$**Mass Balance Equation:** arterial carbon dioxide tension (PaCO~2~), carbon dioxide production (V~CO2~), alveolar ventilation (V~A~), minute ventilation (V~E~), dead space ventilation (V~D~).
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![View of study setting: intra-tracheal catheters for CO~2~ and pressure (P~TRACH~) measurements, tidal volume (V~T~) was measured by respiratory inductive plethysmography (RIP) and CO~2~ was monitored transcutaneously (tcCO~2~). High flow was delivered via nasal cannula.](gr1){#fig1}

![Increase in tracheal pressure (P~TRACH~) due to NHF was associated with a decrease in transcutaneous (Tc) CO~2~ and inspired (in) CO~2~ while respiratory rate was reduced. Tracheal pressure (P~TRACH~), end-tidal CO~2~ (ET CO~2~), tidal volume (V~T~), transcutaneous CO~2~ (TcCO~2~), inspired CO~2,~ (inCO~2~).](gr2){#fig2}
